Literature DB >> 23647733

The first steps on the path toward genomic predictors of behavioral therapy for posttraumatic stress disorder.

Mary-Anne Enoch1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23647733      PMCID： PMC4159136          DOI： 10.1016/j.biopsych.2013.04.005

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  10 in total

Review 1.  Fear extinction and BDNF: translating animal models of PTSD to the clinic.

Authors:  R Andero; K J Ressler
Journal:  Genes Brain Behav       Date:  2012-05-11       Impact factor: 3.449

2.  Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder.

Authors:  Richard A Bryant; Kim L Felmingham; Erin M Falconer; Laarnie Pe Benito; Carol Dobson-Stone; Kerrie D Pierce; Peter R Schofield
Journal:  Biol Psychiatry       Date:  2010-06-15       Impact factor: 13.382

3.  Serotonin transporter polyadenylation polymorphism modulates the retention of fear extinction memory.

Authors:  Catherine A Hartley; Morgan C McKenna; Rabia Salman; Andrew Holmes; B J Casey; Elizabeth A Phelps; Charles E Glatt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

4.  Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder.

Authors:  Dhuha Mushtaq; Arif Ali; Mushtaq A Margoob; Imtiyaz Murtaza; Chittaranjan Andrade
Journal:  J Affect Disord       Date:  2011-09-29       Impact factor: 4.839

5.  Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment.

Authors:  Elisabeth B Binder; Daria Salyakina; Peter Lichtner; Gabriele M Wochnik; Marcus Ising; Benno Pütz; Sergi Papiol; Shaun Seaman; Susanne Lucae; Martin A Kohli; Thomas Nickel; Heike E Künzel; Brigitte Fuchs; Matthias Majer; Andrea Pfennig; Nikola Kern; Jürgen Brunner; Sieglinde Modell; Thomas Baghai; Tobias Deiml; Peter Zill; Brigitta Bondy; Rainer Rupprecht; Thomas Messer; Oliver Köhnlein; Heike Dabitz; Tanja Brückl; Nina Müller; Hildegard Pfister; Roselind Lieb; Jakob C Mueller; Elin Lõhmussaar; Tim M Strom; Thomas Bettecken; Thomas Meitinger; Manfred Uhr; Theo Rein; Florian Holsboer; Bertram Muller-Myhsok
Journal:  Nat Genet       Date:  2004-11-21       Impact factor: 38.330

Review 6.  Variant brain-derived neurotrophic factor Val66Met endophenotypes: implications for posttraumatic stress disorder.

Authors:  Helena Frielingsdorf; Kevin G Bath; Fatima Soliman; JoAnn Difede; B J Casey; Francis S Lee
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

7.  Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults.

Authors:  Elisabeth B Binder; Rebekah G Bradley; Wei Liu; Michael P Epstein; Todd C Deveau; Kristina B Mercer; Yilang Tang; Charles F Gillespie; Christine M Heim; Charles B Nemeroff; Ann C Schwartz; Joseph F Cubells; Kerry J Ressler
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

8.  The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-o-methyltransferase Val(158)Met polymorphism.

Authors:  Iris-Tatjana Kolassa; Stephan Kolassa; Verena Ertl; Andreas Papassotiropoulos; Dominique J-F De Quervain
Journal:  Biol Psychiatry       Date:  2009-11-27       Impact factor: 13.382

9.  The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder.

Authors:  Kim L Felmingham; Carol Dobson-Stone; Peter R Schofield; Gregory J Quirk; Richard A Bryant
Journal:  Biol Psychiatry       Date:  2013-01-08       Impact factor: 13.382

Review 10.  Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity.

Authors:  Robert H Lipsky; Ann M Marini
Journal:  Ann N Y Acad Sci       Date:  2007-12       Impact factor: 5.691
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.